MICA/B expression is inhibited by unfolded protein response and associated with poor prognosis in human hepatocellular carcinoma

Journal of Experimental and Clinical Cancer Research

Volumn 33, Issue 1, 2014, Pages

  Fang, Liang ^a   Gong, Jiuyu ^a,b   Wang, Ying ^a   Liu, Rongrong ^a   Li, Zengshan ^a   Wang, Zhe ^a   Zhang, Yun ^a   Zhang, Chunmei ^a   Song, Chaojun ^a   Yang, Angang ^a   Ting, Jenny P Y ^c   Jin, Boquan ^a   Chen, Lihua ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b Hospital of Hubei Armed Police Corps   (China)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Hepatocellular carcinoma; Innate immunity; MICA B; Natural killer cell; Unfolded protein response

Indexed keywords

LACTATE DEHYDROGENASE; LIGAND; MAJOR HISTOCOMPATIBILITY COMPLEX CLASS 1 RELATED CHAIN A; MAJOR HISTOCOMPATIBILITY COMPLEX CLASS 1 RELATED CHAIN B; TUNICAMYCIN; UNCLASSIFIED DRUG; HEAT SHOCK PROTEIN; HLA ANTIGEN CLASS 1; MHC CLASS I-RELATED CHAIN A; MICB ANTIGEN; MOLECULAR CHAPERONE GRP78;

ARTICLE; CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CANCER TISSUE; CONTROLLED STUDY; CYTOLYSIS; CYTOTOXICITY; CYTOTOXICITY ASSAY; DOWN REGULATION; FLOW CYTOMETRY; HEPATOMA CELL; HEPG2 CELL LINE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNE EVASION; IMMUNOHISTOCHEMISTRY; IMMUNOREGULATION; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; NATURAL KILLER CELL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA PROCESSING; UNFOLDED PROTEIN RESPONSE; WESTERN BLOTTING; GENE EXPRESSION; GENETICS; IMMUNOLOGY; LIVER TUMOR; METABOLISM; MORTALITY; OUTCOME ASSESSMENT; PATHOLOGY; PROGNOSIS; TUMOR CELL LINE; UPREGULATION;

CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CYTOTOXICITY, IMMUNOLOGIC; GENE EXPRESSION; HEAT-SHOCK PROTEINS; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; IMMUNOHISTOCHEMISTRY; KILLER CELLS, NATURAL; LIVER NEOPLASMS; NEOPLASM STAGING; PATIENT OUTCOME ASSESSMENT; PROGNOSIS; PROTEOLYSIS; RNA PROCESSING, POST-TRANSCRIPTIONAL; UNFOLDED PROTEIN RESPONSE; UP-REGULATION;

EID: 84908153858     PISSN: None     EISSN: 17569966     Source Type: Journal    
DOI: 10.1186/s13046-014-0076-7     Document Type: Article

References (28)

1. Nordenstedt H, White DL, El-Serag HB: The changing pattern of epidemiology in hepatocellular carcinoma. Dig Liver Dis 2010, 42(Suppl 3):S206-S214.
2. Aravalli RN, Steer CJ, Cressman EN: Molecular mechanisms of hepatocellular carcinoma. Hepatology 2008, 48 (6):2047-2063.
3. Ishiyama K, Ohdan H, Ohira M, Mitsuta H, Arihiro K, Asahara T: Difference in cytotoxicity against hepatocellular carcinoma between liver and periphery natural killer cells in humans. Hepatology 2006, 43 (2):362-372.
4. Vermijlen D, Luo D, Froelich CJ, Medema JP, Kummer JA, Willems E, Braet F, Wisse E: Hepatic natural killer cells exclusively kill splenic/blood natural killer-resistant tumor cells by the perforin/granzyme pathway. J Leukoc Biol 2002, 72 (4):668-676.
5. Bauer S, Groh V, Wu J, Steinle A, Phillips JH, Lanier LL, Spies T: Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science 1999, 285(5428):727-729.
6. Jinushi M, Takehara T, Tatsumi T, Kanto T, Groh V, Spies T, Kimura R, Miyagi T, Mochizuki K, Sasaki Y, Hayashi N: Expression and role of MICA and MICB in human hepatocellular carcinomas and their regulation by retinoic acid. Int J Cancer 2003, 104(3):354-361.
7. Groh V, Rhinehart R, Secrist H, Bauer S, Grabstein KH, Spies T: Broad tumor-associated expression and recognition by tumor-derived gamma delta T cells of MICA and MICB. Proc Natl Acad Sci U S A 1999, 96(12):6879-6884.
8. Groh V, Rhinehart R, Randolph-Habecker J, Topp MS, Riddell SR, Spies T: Costimulation of CD8alphabeta T cells by NKG2D via engagement by MIC induced on virus-infected cells. Nat Immunol 2001, 2(3):255-260.
9. Armeanu SKM, Baltz KM, Weiss TS, Smirnow I, Steinle A, Lauer UM, Bitzer M, Salih HR: Direct and natural killer cell-mediated antitumor effects of low-dose bortezomib in hepatocellular carcinoma. Clin Cancer Res 2008, 14(11):3520-3528.
10. Al-Rawashdeh FY, Scriven P, Cameron IC, Vergani PV, Wyld L: Unfolded protein response activation contributes to chemoresistance in hepatocellular carcinoma. Eur J Gastroenterol Hepatol 2010, 22(9):1099-1105.
11. Ma Y, Hendershot LM: The role of the unfolded protein response in tumour development: friend or foe? Nat Rev Cancer 2004, 4(12):966-977.
12. Shuda M, Kondoh N, Imazeki N, Tanaka K, Okada T, Mori K, Hada A, Arai M, Wakatsuki T, Matsubara O, Yamamoto N, Yamamoto M: Activation of the ATF6, XBP1 and grp78 genes in human hepatocellular carcinoma: a possible involvement of the ER stress pathway in hepatocarcinogenesis. J Hepatol 2003, 38(5):605-614.
13. Moenner M, Pluquet O, Bouchecareilh M, Chevet E: Integrated endoplasmic reticulum stress responses in cancer. Cancer Res 2007, 67(22):10631-10634.
14. Huang J, Song H, Liu B, Yu B, Wang R, Chen L: Expression of Notch-1 and its clinical significance in different histological subtypes of human lung adenocarcinoma. J Exp Clin Cancer Res 2013, 32:84.
15. Chu JS, Ge FJ, Zhang B, Wang Y, Silvestris N, Liu LJ, Zhao CH, Lin L, Brunetti AE, Fu YL, Wang J, Paradiso A, Xu JM: Expression and prognostic value of VEGFR-2, PDGFR-beta, and c-Met in advanced hepatocellular carcinoma. J Exp Clin Cancer Res 2013, 32:16.
16. Huergo-Zapico L, Acebes-Huerta A, Lopez-Soto A, Villa-Alvarez M, Gonzalez-Rodriguez AP, Gonzalez S: Molecular bases for the regulation of NKG2D ligands in cancer. Front Immunol 2014, 5:106.
17. Watson NF, Spendlove I, Madjd Z, McGilvray R, Green AR, Ellis IO, Scholefield JH, Durrant LG: Expression of the stress-related MHC class I chain-related protein MICA is an indicator of good prognosis in colorectal cancer patients. Int J Cancer 2006, 118(6):1445-1452.
18. McGilvray RW, Eagle RA, Watson NF, Al-Attar A, Ball G, Jafferji I, Trowsdale J, Durrant LG: NKG2D ligand expression in human colorectal cancer reveals associations with prognosis and evidence for immunoediting. Clin Cancer Res 2009, 15(22):6993-7002.
19. de Kruijf EM, Sajet A, van Nes JG, Putter H, Smit VT, Eagle RA, Jafferji I, Trowsdale J, Liefers GJ, van de Velde CJ, Kuppen PJ: NKG2D ligand tumor expression and association with clinical outcome in early breast cancer patients: an observational study. BMC Cancer 2012, 12:24.
20. Duan X, Deng L, Chen X, Lu Y, Zhang Q, Zhang K, Hu Y, Zeng J, Sun W: Clinical significance of the immunostimulatory MHC class I chain-related molecule A and NKG2D receptor on NK cells in pancreatic cancer. Medical oncology (Northwood, London, England) 2011, 28:466-474.
21. Kamimura H, Yamagiwa S, Tsuchiya A, Takamura M, Matsuda Y, Ohkoshi S, Inoue M, Wakai T, Shirai Y, Nomoto M, Aoyagi Y: Reduced NKG2D ligand expression in hepatocellular carcinoma correlates with early recurrence. J Hepatol 2012, 56(2):381-388.
22. Li JJ, Pan K, Gu MF, Chen MS, Zhao JJ, Wang H, Liang XT, Sun JC, Xia JC: Prognostic value of soluble MICA levels in the serum of patients with advanced hepatocellular carcinoma. Chinese journal of cancer 2013, 32:141-148.
23. Akazawa Y, Mott JL, Bronk SF, Werneburg NW, Kahraman A, Guicciardi ME, Meng XW, Kohno S, Shah VH, Kaufmann SH, McNiven MA, Gores GJ: Death receptor 5 internalization is required for lysosomal permeabilization by TRAIL in malignant liver cell lines. Gastroenterology 2009, 136 (7):2365-2376. e2361-2367.
24. Melum E, Karlsen TH, Schrumpf E, Bergquist A, Thorsby E, Boberg KM, Lie BA: Cholangiocarcinoma in primary sclerosing cholangitis is associated with NKG2D polymorphisms. Hepatology 2008, 47(1):90-96.
25. Raulet DH: Roles of the NKG2D immunoreceptor and its ligands. Nat Rev Immunol 2003, 3(10):781-790.
26. Lanier LL: NK cell recognition. Annu Rev Immunol 2005, 23:225-274.
27. Wu JD, Higgins LM, Steinle A, Cosman D, Haugk K, Plymate SR: Prevalent expression of the immunostimulatory MHC class I chain-related molecule is counteracted by shedding in prostate cancer. J Clin Invest 2004, 114(4):560-568.
28. Dambrauskas Z, Svensson H, Joshi M, Hyltander A, Naredi P, Iresjo BM: Expression of major histocompatibility complex class I-related chain A/B (MICA/B) in pancreatic carcinoma. Int J Oncol 2014, 44(1):99-104.